Table 1.

Clinical demographics of 292 human breast tumors

Columbia cohort, n = 131 (%)Sweden cohort, n = 161 (%)Combined, n = 292 (%)
Stage
    I31 (24)0 (0)31 (11)
    II66 (50)160 (99)226 (77)
    III18 (14)0 (0)18 (6)
    IV4 (3)0 (0)4 (1)
    Unknown12 (9)1 (1)13 (4)
PIK3CA mutants by stage
    I9/31 (29)0/0 (0)9/31 (29)
    II14/66 (21)44/160 (28)58/226 (26)
    III3/18 (17)0/0 (0)3/18 (17)
    IV1/4 (25)0/0 (0)1/4 (25)
    Unknown5/12 (42)1/1 (100)6/13 (46)
    All32/131 (24)45/161 (28)77/292 (26)
Median age (y)53 (range, 24-89; n = 122)61 (range, 26-77; n = 160)59 (range, 24-89; n = 282)
Median tumor size (mm)25 (range, 5-90; n = 121)27 (range, 2-50; n = 160)26 (range, 2-90; n = 281)
Estrogen receptor
    Positive85 (65)77 (48)162 (55)
    Negative35 (27)79 (49)114 (39)
    Unknown11 (8)5 (3)16 (5)
Progesterone receptor
    Positive76 (58)66 (41)142 (49)
    Negative44 (34)90 (56)134 (46)
    Unknown11 (8)5 (3)16 (5)
Lymph node
    Positive58 (44)106 (66)164 (56)
    Negative64 (49)54 (34)118 (40)
    Unknown9 (7)1 (1)10 (3)
ERBB2
    Positive44 (34)34 (21)78 (27)
    Negative60 (46)76 (47)136 (47)
    Unknown27 (21)51 (32)78 (27)
Recurrence (any)
    Positive27 (21)48 (30)75 (26)
    Negative92 (70)112 (70)204 (70)
    Unknown12 (9)1 (1)13 (4)
PTEN protein
    Positive0 (0)109 (68)109 (37)
    Negative0 (0)47 (29)47 (16)
    Unknown131 (100)5 (3)136 (47)
Median follow-up time (y)2.6 (range, 0-12.8; n = 121)5.2 (range, 0.1-11.4; n = 160)4.4 (range, 0-12.8; n = 281)